High Risankizumab Induction Dose Rapidly Clears Psoriasis, Reduces Resident Memory Cells

Data from the phase 2 KNOCKOUT study show risankizumab's sustained benefit in reducing memory cells over 52 weeks in psoriasis patients.

Related Keywords

Oregon ,United States ,San Diego ,California ,American ,Andrew Blauvelt ,Oregon Medical Research Center ,American Academy Of Dermatology ,Drug Administration ,American Academy ,Psoriasis Area Severity Index ,Surface Area ,